Our research team consists of several physicians, clinical psychologists, (bio)engineers, a nurse/case manager, and an office manager.
Cancer treatment during pregnancy is discussed and scheduled in concert with specialists from related disciplines. In a multidisciplinary clinical setting, the primary focus is on optimal maternal cancer treatment and fetal well-being. In parallel and where applicable, research items are addressed. For example, children are followed on a regular basis in order to assess the effects, if any, of antenatal exposure to cancer treatment. This strategy has resulted in good clinical experience and very reliable scientific data.
Since its founding, the team has published about 100 scientific papers on cancer and pregnancy and has delivered more than 100 talks on the topic, both internationally and nationally.
KU Leuven is Belgium’s largest and oldest university. UZ Leuven is its network of research hospitals but functions as an autonomous healthcare provider. UZ Leuven is among Europe’s largest hospital systems.
Additional information can be obtained through this website.
Principle Investigator
Frédéric Amant, MD, PhD (°1967), received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998, and his subspecialty training in gynecologic oncology in 2000. He is professor at the KU Leuven in Belgium and at the University of Amsterdam (AMC-UvA) in the Netherlands.
Since july 2015, he is a specialist in Gynecologic Oncology at Antoni van Leeuwenhoek – Netherlands Cancer Institute in Amsterdam, The Netherlands. He has stopped his clinical activities in the University Hospitals (UZ Gasthuisberg) Leuven until July 2020, but remains the principal investigator of the cancer in pregnancy research project in Leuven. He heads the Center for Gynecologic Oncology Amsterdam (CGOA) and the scientific section on Gynaecologic Oncology at KU Leuven.
Frédéric Amant chairs the International Network on ‘Cancer, Infertility and Pregnancy’ (INCIP) of the European Society of Gynecologic Oncology (ESGO).
Frédéric Amant, M.D., Ph.D.
Department of Oncology, KU Leuven
Department of Gynaecological Oncology, UZ Leuven
Herestraat 49, 3000 Leuven, Belgium
Tel:+32 16 34 42 73
Fax:+32 16 34 46 29
Research Team
- Kristel Van Calsteren, M.D., Ph.D., Obstetrics & Gynaecology, UZ Leuven, KU Leuven
- Liesbeth Lenaerts, Ph.D, Bio-engineer, Obstetrics & Gynaecology, KU Leuven
- Indra Van Assche, Msc, Obstetrics & Gynaecology, UZ Leuven, KU Leuven
- Mathilde Van Gerwen, Msc, Obstetrics & Gynaecology, NKI/AVL Amsterdam, The Netherlands
- Evangeline Huis in't Veld , Msc, Obstetrics & Gynaecology, NKI/AVL Amsterdam, The Netherlands
- Joosje Heimovaara, M.D., Obstetrics and Gynaecology, KU Leuven
- Charlotte Maggen, M.D., Obstetrics & Gynaecology, KU Leuven
- Vera Wolters, M.D., Obstetrics & Gynaecology, NKI/AVL Amsterdam, The Netherlands
- Jeroen Blommaert, Engineer, Medical Imaging, UZ Leuven, KU Leuven
- Hanne Lefrère, Bio-engineer, Obstretrics & Gynaecology, KU Leuven
- Ilana Struys, Bio-engineer, Obstetrics & Gynaecology, KU Leuven
- Lara Stroobants, Msc, Obstetrics & Gynaecology, UZ Leuven, KU Leuven
- Katrien Van Tornout, Case Manager, Obstetrics & Gynaecology, UZ Leuven
- Marie-Astrid Vanhoorick, Secretariat Obstetrics & Gynaecology, UZ Leuven
- Diane Wolput, Secretariat Obstetrics & Gynaecology, UZ Leuven
